ClinicalTrials.Veeva

Menu

Effects of Traditional Chinese Medicine on Bronchiectasis Patients

H

Henan University of Traditional Chinese Medicine

Status and phase

Unknown
Phase 3

Conditions

Bronchiectasis

Treatments

Drug: Bufei Huatan granule
Drug: Placebo Bufei Huatan granule
Drug: Placebo Yifei Qinghua granule
Drug: Yifei Qinghua granule

Study type

Interventional

Funder types

Other

Identifiers

NCT03443531
TCM for Bronchiectasis

Details and patient eligibility

About

The aim of this study is to evaluate the effectiveness of Traditional Chinese Medicine (TCM) on patients with clinically stable bronchiectasis by a multi-center, randomized, double-blind, controlled trial: one, TCM treatments based on syndrome differentiation; the other, a placebo of TCM treatment.

Full description

Bronchiectasis is a common and frequently occurring respiratory disease, with more hospitalization rate and mortality, poor quality of life and heavy financial burden. The main clinical manifestations are persistent or recurrent cough, expectoration, sometimes accompanied by hemoptysis, which can cause respiratory dysfunction and chronic pulmonary heart disease. There are some randomized controlled trials of TCM for bronchiectasis, and have the effect in the treatment of bronchiectasis, reducing the number of acute aggravation and alleviating dyspnea. However, some TCM interventions lack comprehensive syndrome differentiation and the placebo control.

This is a multi-center, randomized, double-blind, controlled trial to compare the efficacy to evaluate the effectiveness of TCM on patients with clinically stable bronchiectasis. 216 subjects will be randomly assigned to one therapies (TCM treatments based on syndrome differentiation) and the other therapy (placebo of TCM treatment) for 24 weeks. After the treatment period, the subjects will be followed up for 24 weeks. The primary outcomes include the frequency of bronchiectasis exacerbation, and the secondary outcomes include quality of life (SGRQ, LCQ, QOL-B), pulmonary function, safety observation index.

Enrollment

216 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • A confirmed diagnosis of clinically stable bronchiectasis
  • Age between 18 and 80 years
  • Syndrome differentiation meets criteria of syndrome of Qi deficiency of lung and phlegm-turbidity obstructing the lung, syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung
  • Without participations in other interventional trials in the previous one month
  • With the informed consent signed

Exclusion criteria

  • Current respiratory disorders other than bronchiectasis (e.g. COPD,bronchial asthma, lung cancer,active tuberculosis, Interstitial lung disease, pulmonary thromboembolic, or Other patients who have an impact on the observation of disease)
  • Patients with severe cardiovascular disease (e.g. Acute myocardial infarction,Acute heart failure)
  • Severe liver disease(e.g.Active phase of hepatitis, Cirrhosis, Severe impairment of liver function by portal hypertension)
  • Severe renal disease(e.g. renal transplant, dialysis)
  • Patients with large hemoptysis in the last month
  • Pregnant and lactating women
  • Insanity, Dementia, and all kinds of Psychosis
  • Smoking patients (Years of smoking10/ package year)
  • Participating in other clinical trials with other interventions;
  • Allergic to the used medicine.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

216 participants in 2 patient groups, including a placebo group

TCM
Experimental group
Description:
Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
Treatment:
Drug: Bufei Huatan granule
Drug: Yifei Qinghua granule
placebo TCM
Placebo Comparator group
Description:
Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
Treatment:
Drug: Placebo Yifei Qinghua granule
Drug: Placebo Bufei Huatan granule

Trial contacts and locations

0

Loading...

Central trial contact

Zhiwan Wang, Doctor; Yang Xie, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems